Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Accumulated Expenses: 2020-2024

Historic Accumulated Expenses for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to $140.2 million.

  • Apellis Pharmaceuticals' Accumulated Expenses rose 0.35% to $140.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.3 million, marking a year-over-year increase of 0.35%. This contributed to the annual value of $140.2 million for FY2024, which is 9.68% up from last year.
  • As of FY2024, Apellis Pharmaceuticals' Accumulated Expenses stood at $140.2 million, which was up 9.68% from $127.8 million recorded in FY2023.
  • Apellis Pharmaceuticals' Accumulated Expenses' 5-year high stood at $140.2 million during FY2024, with a 5-year trough of $25.0 million in FY2020.
  • For the 3-year period, Apellis Pharmaceuticals' Accumulated Expenses averaged around $121.0 million, with its median value being $127.8 million (2023).
  • Its Accumulated Expenses has fluctuated over the past 5 years, first soared by 312.96% in 2021, then fell by 7.85% in 2022.
  • Over the past 5 years, Apellis Pharmaceuticals' Accumulated Expenses (Yearly) stood at $25.0 million in 2020, then surged by 312.96% to $103.2 million in 2021, then fell by 7.85% to $95.1 million in 2022, then soared by 34.34% to $127.8 million in 2023, then increased by 9.68% to $140.2 million in 2024.